A quarter-century of pneumococcal protection: estimated global impact of PCV7, PCV13, and PCV20 in children <5 years old

Background Streptococcus pneumoniae causes pneumococcal diseases, disproportionately affecting children aged <5 years. Pneumococcal conjugate vaccines (PCVs) have been implemented globally, substantially reducing the disease burden. This study estimated the global public health impact of PCV7, PCV13, and PCV20 in children aged <5 years over 25 years (2000–2025). Methods The vaccine-specific direct effects of PCV7, PCV13, and PCV20 on invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) in children aged <5 years were estimated over a 25-year period using a previously described PCV impact model. The model was parameterized using epidemiology data, population estimates, and published literature providing vaccine effectiveness, incidence, and mortality estimates. Results Between 2000 and 2025, approximately 682 million children aged <5 years were vaccinated globally with PCV7, PCV13, or PCV20, preventing an estimated ~451 million cases of pneumococcal disease and ~1.8 million deaths. AOM accounted for approximately 91% of cases prevented, followed by pneumonia (8%) and IPD (1%), while pneumonia prevention accounted for the majority of deaths averted. PCV13 contributed to more than 95% of the total estimated cases prevented, reflecting its widespread global adoption. The contribution of PCV20 was limited both by its recent introduction and low uptake to date. Conclusions PCV7, PCV13, and PCV20 implementation was estimated to have reduced pneumococcal disease and mortality among young children worldwide. Continued use of effective vaccines such as PCV13 remains critical, while broader adoption of higher-valency options, when feasible, may provide additional public health benefits by addressing evolving pneumococcal serotype epidemiology.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-11-21
DOI
https://doi.org/10.1016/j.vaccine.2026.129382
Primary Topic
Pneumonia and Respiratory Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A quarter-century of pneumococcal protection: estimated global impact of PCV7, PCV13, and PCV20 in children <5 years old

Sophie A. Warren, Mina Moawad, Desmond Dillon-Murphy, Mark Hermannes Rozenbaum et al.
Vaccine
Pneumonia and Respiratory Infections
article

A quarter-century of pneumococcal protection: estimated global impact of PCV7, PCV13, and PCV20 in children <5 years old

Sophie A. Warren, Mina Moawad, Desmond Dillon-Murphy, Mark Hermannes Rozenbaum, Ruth Chapman, Deepak Alexander
article en

Abstract

Background Streptococcus pneumoniae causes pneumococcal diseases, disproportionately affecting children aged <5 years. Pneumococcal conjugate vaccines (PCVs) have been implemented globally, substantially reducing the disease burden. This study estimated the global public health impact of PCV7, PCV13, and PCV20 in children aged <5 years over 25 years (2000–2025). Methods The vaccine-specific direct effects of PCV7, PCV13, and PCV20 on invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) in children aged <5 years were estimated over a 25-year period using a previously described PCV impact model. The model was parameterized using epidemiology data, population estimates, and published literature providing vaccine effectiveness, incidence, and mortality estimates. Results Between 2000 and 2025, approximately 682 million children aged <5 years were vaccinated globally with PCV7, PCV13, or PCV20, preventing an estimated ~451 million cases of pneumococcal disease and ~1.8 million deaths. AOM accounted for approximately 91% of cases prevented, followed by pneumonia (8%) and IPD (1%), while pneumonia prevention accounted for the majority of deaths averted. PCV13 contributed to more than 95% of the total estimated cases prevented, reflecting its widespread global adoption. The contribution of PCV20 was limited both by its recent introduction and low uptake to date. Conclusions PCV7, PCV13, and PCV20 implementation was estimated to have reduced pneumococcal disease and mortality among young children worldwide. Continued use of effective vaccines such as PCV13 remains critical, while broader adoption of higher-valency options, when feasible, may provide additional public health benefits by addressing evolving pneumococcal serotype epidemiology.

VaccineVol. 96
Pfizer (United States) (US), Pfizer (Netherlands) (NL), Thermo Fisher Scientific (United Kingdom) (GB)
Pneumonia and Respiratory Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon